Transcode Therapeutics price target lowered to $10 from $20 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Transcode Therapeutics (RNAZ) to $10 from $20 and keeps a Buy rating on the shares. The firm updated the company’s model following the release of its annual filing. It cites Transcode’s latest equity raises for the target cut and assumes the company’s current cash and equivalents following the raise are sufficient to fund operations into 2026.